Acticor Biotech (ALACT)

Executive Summary

Acticor Biotech is a French biotechnology company founded in 2013, headquartered in Paris, and listed on Euronext Growth under ticker ALACT. The company specializes in developing innovative antibody-based therapeutics for acute ischemic stroke and other thrombotic diseases. Its lead candidate is a novel therapeutic designed to improve patient outcomes in time-critical emergency settings, addressing a significant unmet need in stroke care where rapid intervention is crucial. Acticor's approach leverages monoclonal antibodies to target platelet aggregation and thrombus formation, aiming to provide a safer and more effective treatment alternative to current standards of care. The company operates in the competitive landscape of biologics and antibodies, with a focus on preclinical and clinical stage assets. Despite limited public clinical data, Acticor's pipeline is centered around its proprietary platform. The company has not yet disclosed specific milestone timelines, but typical catalysts for such biotech firms include initiation of Phase II/III trials, interim data readouts, or regulatory interactions. Given the high-risk nature of stroke drug development and the company's early stage, the conviction score is moderate. Key upcoming catalysts could include a Phase Ib/IIa interim analysis in acute ischemic stroke, potential partnership or licensing deals, and grant funding announcements. Investors should monitor for updates on clinical trial registrations and scientific presentations at major conferences.

Upcoming Catalysts (preview)

• Q1 2027Interim Data from Phase Ib/IIa Trial in Acute Ischemic Stroke40% success
• Q3 2026Strategic Partnership for Co-Development or Regional Licensing35% success
• Q4 2026Grant or Non-Dilutive Funding from European/EU Initiatives50% success